Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Biotechnology

1594

The biotechnology industry encompasses the spectrum of life science-based research companies developing products and services for a wide variety of industries and applications. The industry holds the promise of transformative technologies from agriculture to materials science to environmental science to medicine. In agriculture, biotech products enhance crop yield, advance the nutritional value and quality of crops and livestock, and improve the efficacy and safety of pesticides.
In material science, biotechnology is adding to advances in polymer science and the coatings industry. In environmental science, biotech has contributed innovative solutions to environmental clean-up and waste management.

The biggest direct impact of biotechnology, and the biggest market for its products, is in medicine and healthcare. The biotechnology industry is, in many ways, becoming the research and development engine of the pharmaceutical industry. The tools and techniques of genetic analysis and manipulation are at the heart of the drug discovery process, and many of the largest biotech firms have been transformed over the past decade into pharmaceutical and biopharmaceutical giants.

The biotechnology category covers the companies, technologies, tools, and applications of the advanced life science sector. Included are reports on research methods and equipment such as liquid chromatography, mass spectroscopy, genetic sequencing, gene expression, etc. There are also reports on the business of biotechnology, mergers & acquisitions, and funding. Insofar as the sector intersects with the pharmaceutical industry, there are also reports on product pipelines, strategies for drug development and manufacturing such as biogenerics, biosimilars and biomanufacturing. Reports cover so-called green- and white-biotech sectors as well.

RSS Feeds

All reports in Biotechnology

< prev 5  6  7  8  9  10  11  12  13  14  next >
Genzyme Corporation (GENZ) - Financial and Strategic SWOT Analysis Review
2/23/2012 | published by: GlobalData
... Its products and services are focused on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease. It is developing products focused on cardiovascular disease, neurodegenerative diseases and other areas of unmet medical ...  |  more...
$125.00
Cord Blood Database
2/23/2012 | published by: BioInformant Worldwide, L.L.C.
... you want to sell to cord blood banks? Do you recognize the huge population of potential clients this market represents? If so, this may be a critical resource for your business. To allow you to ...  |  more...
$995.00
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
2/23/2012 | published by: GlobalData
... broad product portfolio, which includes innovative medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. The company is focused in areas of Cardiovascular and Metabolism; Oncology; Neuroscience and Ophthalmics; Respiratory; Immunology and ...  |  more...
$125.00
Food Traceability: Technologies and Global Markets
2/23/2012 | published by: BCC Research
...   Use this report to:   Identify and categorize the global food traceability market with respect to equipment, services, software, technologies and applications   Focus on the strategies implemented by the key market players to ...  |  more...
$4,850.00
Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review
2/23/2012 | published by: GlobalData
... diseases. The products developed by the company are designed to treat life-threatening diseases or chronic debilitating conditions. The key products marketed by Celgene include Revlimid (lenalidomide), VIDAZA, Thalomid (thalidomide), ABRAXANE and ISTODAX. There are more ...  |  more...
$125.00
Conference Documentation: CBRN-E Asia Pacific
2/23/2012 | published by: SMI Publishing, Ltd
... will focus on regional and international prevent and prepare initiatives which will allow you to assess how nations in Asia Pacific and the rest of the world are preparing themselves for the modern era attack. ...  |  more...
$800.00
Global Tissue Engineering and Regeneration Market 2011-2015
2/22/2012 | published by: Infiniti Research Limited
... in the Skin Integumentary Clinical segment. The Global Tissue Engineering and Regeneration market has also been witnessing new regulations for regenerative medicines in Europe. However, lack of specialists in the market could pose a challenge ...  |  more...
$1,500.00
Biologicals in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... cancer. In addition, there are 17 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 676 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives ...  |  more...
$3,749.00
Analytical Tool - Cancer Therapeutic Antibodies
2/21/2012 | published by: BioSeeker Group AB
... time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current ...  |  more...
$5,924.00
Analytical Tool - Antibodies and Peptides in Oncology
2/21/2012 | published by: BioSeeker Group AB
... competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  more...
$8,925.00
CSL Limited - SWOT Analysis
2/21/2012 | published by: MarketLine
... summary analysis of its key revenue lines and strategy. CSL Limited (CSL) is a biopharmaceutical group engaged in the R&D, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL invests in the development of ...  |  more...
$125.00
Antibodies in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... of therapeutic antibodies. There are today 290 companies plus partners developing 538 antibody drugs in 1245 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over ...  |  more...
$2,249.00
Gene Therapy in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... years amount to another 94 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 88 different targets. ...  |  more...
$2,249.00
RNA Interference Therapy in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... in 75 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 23 drugs. Rna Interference Therapy In Oncology Drug Pipeline Update lists all drugs and ...  |  more...
$1,499.00
Wound Care in Australia
2/21/2012 | published by: Euromonitor International
... result of ageing. As consumers get older a number of factors combine to increase demand for wound care: not only are they increasingly prone to falls, but it also takes longer for wounds to heal. ...  |  more...
$900.00
Analytical Tool - Apoptosis in Oncology
2/21/2012 | published by: BioSeeker Group AB
... time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current ...  |  more...
$4,650.00
CSL Limited - Strategy and SWOT Report
2/21/2012 | published by: MarketLine
... summary analysis of its key revenue lines and strategy. CSL Limited (CSL) is a biopharmaceutical group engaged in the R&D, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL invests in the development of ...  |  more...
$150.00
Conference Documentation: Advances and Progress in Drug Design
2/21/2012 | published by: SMI Publishing, Ltd
... companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs. Many pharmaceutical and biotechnology companies are now searching for effective strategies to improve hit-to-lead conversion and to identify unsuccessful compounds early ...  |  more...
$800.00
Analytical Tool - Protein Kinase Inhibitors in Oncology
2/21/2012 | published by: BioSeeker Group AB
... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  more...
$5,325.00
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
2/21/2012 | published by: BioSeeker Group AB
... therapy drugs in 520 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 177 drugs. Nucleic Acid Therapies In ...  |  more...
$2,249.00
Wound Care in Indonesia
2/20/2012 | published by: Euromonitor International
... and enjoy good geographic penetration in the country. Traditional retail outlets such as warungs usually sell sticking plasters by the strip, which makes the product very affordable to most Indonesians, as each strip cost merely ...  |  more...
$900.00
The Outlook for Pharmaceuticals in Central Asia (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... markets of Central Asia contrast well; China and India are two of the largest pharmaceutical markets with very large economies, whilst Bangladesh and Pakistan are two of the smallest pharmaceutical markets with significantly smaller economies.  |  more...
$3,630.00
The Outlook for Pharmaceuticals in Western Europe (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... market. Growth, however, will be tempered somewhat by the effects of the global economic recession in the short term. The leading markets are projected to average a CAGR of 2.1% in US dollar terms up ...  |  more...
$3,630.00
The Outlook for Pharmaceuticals in the Middle East and North Africa (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... five MENA markets covered in this collection will represent a combined GDP of US$2.5 trillion in 2016, led by Turkey and Saudi Arabia. Economic development is changing the epidemiological health profile in the region, with ...  |  more...
$3,630.00
The Outlook for Pharmaceuticals in Northern Europe (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
The Northern European countries are projected to represent a combined pharmaceutical market value of over US$26 billion at retail prices by 2016.  |  more...
$3,630.00
< prev 5  6  7  8  9  10  11  12  13  14  next >